Skip to content
mapperlab
← Dashboard
Stock

SGRY

Surgery Partners, Inc.
Latest close $144 of 27 marquee funds currently hold1 CUSIP mapped
Current holders
4
27 funds tracked
Ever held
10
Current + past
New this quarter
1
Exited this quarter
0

Marquee-fund ownership over time

May 17, 2021Nov 14, 2024Nov 13, 2025May 15, 2026
Now
4

This quarter's activity

New positions opened

Positions exited

None.

Current holders

Sorted by tenure (longest first)
FundEntry priceLatest closeReturn on entry
Citadel Advisors$29$14-52%
Millennium Management re-entered$29$14-52%
AQR Capital Management re-entered$26$14-46%
Glenview Capital$23$14-38%

“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.

Past holders

Funds that exited at some point
FundEntry → ExitReturn
Two Sigma Investments→ $16-46%
Renaissance Technologies→ $15+1%
Point72 Asset Management→ $23-23%
D.E. Shaw→ $26-11%
Bridgewater Associates→ $26-12%
Maverick Capital→ $51-3%

Insider activity

Form 4 — officers, directors, 10%+ owners

Filed within two business days of each transaction by anyone with material insider status at Surgery Partners, Inc.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.

Filings · last 30d
7
Filings · last 90d
12
Total on file
371
Recent SEC buffer
Most recent
Jun 9, 2026

30d / 90d windows measured from Jun 9, 2026 — the most recent Form 4 on file — not from today.

Showing 15 of 371 recent Form 4 filings. Browse all on EDGAR ↗

Fundamentals

XBRL · Surgery Partners, Inc.

Annual figures sourced directly from Surgery Partners, Inc.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.

Revenue
$3.31B
FY2025+6% YoY
Net income
-$77.9M
FY2025+54% YoY
EPS (diluted)
$-0.6100
FY2025+54% YoY
Free cash flow(?)
$195.6M
FY2025-7% YoY

Recent SEC filings

10-K · 10-Q · 8-K · 13D/G · proxy

The most recent material filings for Surgery Partners, Inc. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.

Trade history

Every open→close lifecycle across tracked funds
FundOpen dateClose dateOpen priceClose price / currentReturn
AQR Capital ManagementQ2 2026open$14$14-0%
Millennium ManagementQ1 2026open$16$14-11%
Renaissance TechnologiesQ4 2025Q1 2026$15$15+1%
Glenview CapitalQ3 2025open$23$14-38%
AQR Capital ManagementQ1 2025Q2 2025$26$24-9%
Millennium ManagementQ1 2025Q4 2025$26$15-41%
Bridgewater AssociatesQ3 2024Q4 2024$29$26-12%
Citadel AdvisorsQ3 2024open$29$14-52%
Two Sigma InvestmentsQ3 2024Q1 2026$29$16-46%
D.E. ShawQ3 2024Q1 2025$29$26-11%
Millennium ManagementQ3 2024Q4 2024$29$25-15%
Point72 Asset ManagementQ3 2024Q3 2025$29$23-23%
Maverick CapitalQ2 2021Q4 2021$53$51-3%
Caveats
  • Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
  • Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
  • “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
  • Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
  • Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.